- Home
- GENI vs MLYS Comparison
GENI vs MLYS Comparison
Compare GENI & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENI | MLYS |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | GENI | MLYS |
|---|---|---|
| Price | $8.19 | $31.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 7 |
| Target Price | $14.59 | ★ $47.33 |
| AVG Volume (30 Days) | ★ 4.5M | 1.2M |
| Earning Date | 03-03-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $604,524,000.00 | N/A |
| Revenue This Year | $30.99 | N/A |
| Revenue Next Year | $20.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.70 | N/A |
| 52 Week Low | $8.13 | $8.24 |
| 52 Week High | $13.73 | $47.65 |
Technical Indicators
Market Signals| Indicator | GENI | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 22.80 | 37.64 |
| Support Level | $9.50 | $32.05 |
| Resistance Level | $9.75 | $33.63 |
| Average True Range (ATR) | 0.38 | 1.57 |
| MACD | -0.16 | 0.01 |
| Stochastic Oscillator | 1.96 | 22.27 |
Price Performance
Historical ComparisonAbout GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas including Sports Technology and Services; Betting Technology, Content and Services; and Media Technology, Content and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content and Services division. Geographically, the company derives a majority of its revenue from Europe.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.